Fingerprint
Dive into the research topics of 'Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder
Kathryn M. Connor, Paulette Ceesay, Jill Hutzelmann, Duane Snavely, Andrew D. Krystal, Madhukar H. Trivedi, Michael Thase, Christopher Lines, W. Joseph Herring, David Michelson
Research output: Contribution to journal › Article › peer-review
17
Scopus
citations